Advertisement
YOU ARE HERE: LAT HomeCollectionsGeron Corp
IN THE NEWS

Geron Corp

NEWS
October 11, 2010
Make way for the future, at least when it comes to stem-cell therapy. An Atlanta hospital treated the first patient Friday in a nationwide clinical trial of a therapy derived from embryonic stem cells. The clinical trial, run by pharmaceutical company Geron Corp., seeks to test whether experimental cells, known as GRNOPC1, are safe for use in humans and whether patients will regain neuromuscular control in their legs and torsos. The Shepherd Center in Atlanta, a rehabilitation hospital that specializes in people who have spinal cord injuries or disease, and Northwestern Medicine in Chicago are currently enrolling patients in the trial.
Advertisement
HEALTH
November 21, 2011 | By Eryn Brown, Los Angeles Times
For patients paralyzed by spinal cord injuries, Geron Corp.'s stem cell research was the shining hope. The biotech firm showered scientists with millions of dollars to develop a treatment to reverse spinal damage. The therapy was the first treatment derived from embryonic stem cells to be cleared by the Food and Drug Administration for testing in humans. But last week, Geron abruptly pulled the plug on its pioneering trial and the rest of its stem cell business, including early work on treatments for heart ailments, diabetes and other diseases.
BUSINESS
September 7, 2006 | From Bloomberg News
Geron Corp. and Advanced Cell Technology Inc. agreed to settle a patent dispute over a pioneering cloning technology that led to the creation of Dolly the sheep. Advanced Cell and the University of Massachusetts agreed to end their appeal and give up certain patents for animal cloning technology while keeping rights to a cloning method for human use, Advanced Cell said. Menlo Park, Calif.-based Geron keeps the rights to use the technology in animal cloning.
CALIFORNIA | LOCAL
November 23, 1995 | From Times staff reports
Scientists have linked cardiovascular disease to an age-related breakdown of telomeres, repetitive strings of DNA on the ends of chromosomes. Every time a cell divides, a bit of the telomere is lost. Ultimately, when all the telomere is gone, the cells are unable to divide. Previous research has shown that cancer cells are able to prevent the telomeres from being shortened, and are thus able to continue dividing indefinitely. A team from Geron Corp. reports in the Proceedings of the National Academy of Sciences that blood vessel cells involved in atherosclerosis have shortened telomeres, suggesting that they have prematurely aged for an as-yet-unknown reason.
BUSINESS
September 7, 1993 | James M. Gomez / Times staff writer
Oxford Bioscience Partners of Costa Mesa, which also has an office in Stamford, Conn., has also just received some fresh money. The venture capital concern, which specializes in the health care industry--including biotechnology, biomedical and health services--has just raised nearly $54 million to invest in cash-needy businesses in Orange County and throughout the nation. "We are looking at a number of companies right now," said fund partner Edmund M. Olivier.
Los Angeles Times Articles
|